References
- Clynes RA, Desjarlais JR. Redirected T cell cytotoxicity in cancer therapy. Annu Rev Med. 2019;70:437–10. doi:https://doi.org/10.1146/annurev-med-062617-035821.
- Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585–608.
- Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9(2):182–212. doi:https://doi.org/10.1080/19420862.2016.1268307.
- Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, et al. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin Cancer Res. 2018;24:4785–97. doi:https://doi.org/10.1158/1078-0432.CCR-18-0455.
- Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, Bodmer W, Lehmann S, Hofer T, Hosse RJ, et al. A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors. Clin Cancer Res. 2016;22:3286–97. doi:https://doi.org/10.1158/1078-0432.CCR-15-1696.
- Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, Lipp S, Merino J, Prosper F, Emde M, et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell. 2017;31:396–410. doi:https://doi.org/10.1016/j.ccell.2017.02.002.
- Bacac M, Klein C, Umana P. CEA TCB: a novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors. Oncoimmunology. 2016;5:e1203498. doi:https://doi.org/10.1080/2162402X.2016.1203498.
- Klein C, Schaefer W, Regula JT, Dumontet C, Brinkmann U, Bacac M, Umaña P. Engineering therapeutic bispecific antibodies using CrossMab technology. Methods. 2019;154:21–31. doi:https://doi.org/10.1016/j.ymeth.2018.11.008.
- Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick C, Kubbies M, Klein C, Umaña P, Mössner E, et al. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng Des Sel. 2016;29:457–66. doi:https://doi.org/10.1093/protein/gzw040.
- Rius Ruiz I, Vicario R, Morancho B, Morales CB, Arenas EJ, Herter S, Freimoser-Grundschober A, Somandin J, Sam J, Ast O, et al. p95HER2-T cell bispecific antibody for breast cancer treatment. Sci Transl Med. 2018;10:eaat1445. doi:https://doi.org/10.1126/scitranslmed.aat1445.
- Petrova G, Ferrante A, Gorski J. Cross-reactivity of T cells and its role in the immune system. Crit Rev Immunol. 2012;32:349–72. doi:https://doi.org/10.1615/CritRevImmunol.v32.i4.50.
- Hebeisen M, Allard M, Gannon PO, Schmidt J, Speiser DE, Rufer N. Identifying individual T cell receptors of optimal avidity for tumor antigens. Front Immunol. 2015;6:582. doi:https://doi.org/10.3389/fimmu.2015.00582.
- He Q, Liu Z, Liu Z, Lai Y, Zhou X, Weng J. TCR-like antibodies in cancer immunotherapy. J Hematol Oncol. 2019;12:99. doi:https://doi.org/10.1186/s13045-019-0788-4.
- Hoydahl LS, Frick R, Sandlie I, Loset GA. Targeting the MHC ligandome by use of TCR-like antibodies. Antibodies (Basel). 2019;8(2):32. doi:https://doi.org/10.3390/antib8020032.
- Yang X, Xie S, Yang X, Cueva JC, Hou X, Tang Z, Yao H, Mo F, Yin S, Liu A, et al. Opportunities and challenges for antibodies against intracellular antigens. Theranostics. 2019;9(25):7792–806. doi:https://doi.org/10.7150/thno.35486.
- Chang AY, Gejman RS, Brea EJ, Oh CY, Mathias MD, Pankov D, Casey E, Dao T, Scheinberg DA. Opportunities and challenges for TCR mimic antibodies in cancer therapy. Expert Opin Biol Ther. 2016;16:979–87. doi:https://doi.org/10.1080/14712598.2016.1176138.
- Dubrovsky L, Dao T, Gejman RS, Brea EJ, Chang AY, Oh CY, Casey E, Pankov D, Scheinberg DA. T cell receptor mimic antibodies for cancer therapy. Oncoimmunology. 2016;5:e1049803. doi:https://doi.org/10.1080/2162402X.2015.1049803.
- Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N, et al. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nat Biotechnol. 2015;33:1079–86. doi:https://doi.org/10.1038/nbt.3349.
- Dao T, Liu C, Scheinberg DA. Approaching untargetable tumor-associated antigens with antibodies. Oncoimmunology. 2013;2(e24678):e24678. doi:https://doi.org/10.4161/onci.24678.
- Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323–37. doi:https://doi.org/10.1158/1078-0432.CCR-09-0737.
- Rossi G, Minervini MM, Carella AM, Melillo L, Cascavilla N. Wilms’ tumor gene (WT1) expression and minimal residual disease in acute myeloid leukemia. In: Tumor W, van den Heuvel-Eibrink MM, editor. Wilms tumor. Brisbane (AU): Codon Publications; 2016. p. 273–285.
- Doubrovina E, Carpenter T, Pankov D, Selvakumar A, Hasan A, O’Reilly RJ. Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias. Blood. 2012;120:1633–46. doi:https://doi.org/10.1182/blood-2011-11-394619.
- Gejman RS, Jones HF, Klatt MG, Chang AY, Oh CY, Chandran SS, Korontsvit T, Zakahleva V, Dao T, Klebanoff CA, Scheinberg DA. Identification of the targets of T cell receptor therapeutic agents and cells by use of a high throughput genetic platform. Cancer Immunol Res. 2020;8(5):672–684. doi:https://doi.org/10.1158/2326-6066.CIR-19-0745.
- Oren R, Hod-Marco M, Haus-Cohen M, Sharyn T, Blat D, Duvshani N, Denkberg G, Elbaz Y, Benchetrit F, Eshhar Z, et al. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds. J Immunol. 2014;193(11):5733–43. doi:https://doi.org/10.4049/jimmunol.1301769.
- Lee HY, Register A, Shim J, Contreras E, Wu Q, Jiang G. Characterization of a single reporter-gene potency assay for T-cell-dependent bispecific molecules. MAbs. 2019;11:1245–53. doi:https://doi.org/10.1080/19420862.2019.1640548.
- Shaw JP, Utz PJ, Durand DB, Toole JJ, Emmel EA, Crabtree GR. Identification of a putative regulator of early T cell activation genes. Science. 1988;241:202–05. doi:https://doi.org/10.1126/science.3260404.
- Rincon M, Flavell RA. Regulation of AP-1 and NFAT transcription factors during thymic selection of T cells. Mol Cell Biol. 1996;16:1074–84. doi:https://doi.org/10.1128/MCB.16.3.1074.
- Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004;173:945–54. doi:https://doi.org/10.4049/jimmunol.173.2.945.
- Rosskopf S, Leitner J, Paster W, Morton LT, Hagedoorn RS, Steinberger P, Heemskerk MHM. A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies. Oncotarget. 2018;9:17608–19. doi:https://doi.org/10.18632/oncotarget.24807.
- Fiering S, Northrop JP, Nolan GP, Mattila PS, Crabtree GR, Herzenberg LA. Single cell assay of a transcription factor reveals a threshold in transcription activated by signals emanating from the T-cell antigen receptor. Genes Dev. 1990;4:1823–34. doi:https://doi.org/10.1101/gad.4.10.1823.
- Tan MP, Dolton GM, Gerry AB, Brewer JE, Bennett AD, Pumphrey NJ, Jakobsen BK, Sewell AK. Human leucocyte antigen class I-redirected anti-tumour CD4(+) T cells require a higher T cell receptor binding affinity for optimal activity than CD8(+) T cells. Clin Exp Immunol. 2017;187:124–37. doi:https://doi.org/10.1111/cei.12828.
- Krummey SM, Martinez RJ, Andargachew R, Liu D, Wagener M, Kohlmeier JE, Evavold BD, Larsen CP, Ford ML. Low-affinity memory CD8+ T cells mediate robust heterologous immunity. J Immunol. 2016;196:2838–46. doi:https://doi.org/10.4049/jimmunol.1500639.
- Gee MH, Sibener LV, Birnbaum ME, Jude KM, Yang X, Fernandes RA, Mendoza JL, Glassman CR, Garcia KC. Stress-testing the relationship between T cell receptor/peptide-MHC affinity and cross-reactivity using peptide velcro. Proc Natl Acad Sci USA. 2018;115:E7369–E78. doi:https://doi.org/10.1073/pnas.1802746115.
- Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA 3rd, Smith HO. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods. 2009;6:343–45. doi:https://doi.org/10.1038/nmeth.1318.
- Giry-Laterriere M, Verhoeyen E, Salmon P. Lentiviral vectors. Methods Mol Biol. 2011;737:183–209.
- Schmittnaegel M, Hoffmann E, Imhof-Jung S, Fischer C, Drabner G, Georges G, Klein C, Knoetgen H. A new class of bifunctional major histocompatibility class i antibody fusion molecules to redirect CD8 T cells. Mol Cancer Ther. 2016;15:2130–42. doi:https://doi.org/10.1158/1535-7163.MCT-16-0207.
- Joglekar AV, Leonard MT, Jeppson JD, Swift M, Li G, Wong S, Peng S, Zaretsky JM, Heath JR, Ribas A, et al. T cell antigen discovery via signaling and antigen-presenting bifunctional receptors. Nat Methods. 2019;16:191–98. doi:https://doi.org/10.1038/s41592-018-0304-8.
- Kisielow J, Obermair FJ, Kopf M. Deciphering CD4(+) T cell specificity using novel MHC-TCR chimeric receptors. Nat Immunol. 2019;20:652–62. doi:https://doi.org/10.1038/s41590-019-0335-z.
- van der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015;14:499–509.
- Davis SJ, van der Merwe PA. The structure and ligand interactions of CD2: implications for T-cell function. Immunol Today. 1996;17:177–87. doi:https://doi.org/10.1016/0167-5699(96)80617-7.
- Alonso-Camino V, Sanchez-Martin D, Compte M, Nunez-Prado N, Diaz RM, Vile R, Alvarez-Vallina L. CARbodies: human antibodies against cell surface tumor antigens selected from repertoires displayed on T cell chimeric antigen receptors. Mol Ther Nucleic Acids. 2013;2:e93. doi:https://doi.org/10.1038/mtna.2013.19.
- Rydzek J, Nerreter T, Peng H, Jutz S, Leitner J, Steinberger P, Einsele H, Rader C, Hudecek M. Chimeric antigen receptor library screening using a novel NF-kappaB/NFAT reporter cell platform. Mol Ther. 2019;27:287–99. doi:https://doi.org/10.1016/j.ymthe.2018.11.015.
- Darowski D, Jost C, Stubenrauch K, Wessels U, Benz J, Ehler A, Freimoser-Grundschober A, Brünker P, Mössner E, Umaña P, Kobold S, Klein C. P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation. Protein Eng Des Sel. 2019;32:207–18. doi: https://doi.org/10.1093/protein/gzz027.
- Darowski D, Kobold S, Jost C, Klein C. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells. MAbs. 2019;11:621–31. doi:https://doi.org/10.1080/19420862.2019.1596511.
- Gopalakrishnan R, Matta H, Choi S, Natarajan V, Prins R, Gong S, Zenunovic A, Narasappa N, Patel F, Prakash R, Chaudhary V. A novel luciferase-based assay for the detection of chimeric antigen receptors. Sci Rep. 2019;9:1957. doi:https://doi.org/10.1038/s41598-018-38258-z.
- Barrett J. Expanding the antigenic repertoire of CAR-T cells with “TCR-like” antibody specificity. Cytotherapy. 2016;18(8):929–30. doi:https://doi.org/10.1016/j.jcyt.2016.06.007.
- Akatsuka Y. TCR-like CAR-T cells targeting MHC-bound minor histocompatibility antigens. Front Immunol. 2020;11:257. doi:https://doi.org/10.3389/fimmu.2020.00257.
- Rafiq S, Purdon TJ, Daniyan AF, Koneru M, Dao T, Liu C, Scheinberg DA, Brentjens RJ. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms tumor 1 antigen. Leukemia. 2017;31(8):1788–97. doi:https://doi.org/10.1038/leu.2016.373.
- Maus MV, Plotkin J, Jakka G, Steward-Jones G, Riviere I, Merghoub T, Wolchok J, Renner C, Sadelain M. A MHC-restricted antibody-based chimeric receptor requires TCR-like affinity to maintain antigen specificity. Mol Ther Oncol. 2016;3:1–9. doi:https://doi.org/10.1038/mto.2016.23.
- Sun L, Guo H, Jiang R, Lu L, Liu T, He X. Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma. Tumour Biol. 2016;37(1):799–806. doi:https://doi.org/10.1007/s13277-015-3845-9.
- Liu H, Xu Y, Xiang J, Long L, Green S, Yang Z, Zimdahl B, Lu J, Cheng N, Horan LH, et al. Targeting Alpha-Fetoprotein (AFP)-MHC complex with CAR T-cell therapy for liver cancer. Clin Cancer Res. 2017;23(2):478–88. doi:https://doi.org/10.1158/1078-0432.CCR-16-1203.
- Zhang G, Wang L, Cui H, Wang X, Zhang G, Ma J, Han H, He W, Wang W, Zhao Y, et al. Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor. Sci Rep. 2014;4:3571. doi:https://doi.org/10.1038/srep03571.